bone marker

bone marker

Any biochemical marker that indicates bone breakdown, which can be used to predict individual fracture risk when bone mineral density measurement does not provide a clear answer.

Bone markers
Bone formation markers
• Serum total alkaline phosphatase;
• Serum bone—specific alkaline phosphatase;
• Serum osteocalcin;
• Serum type-1 procollagen.

Bone resorption markers
• Urine hydroxyproline;
• Urine total pyridinoline (PYD);
• Urine free deoxypyridinoline (DPD);
• Urine collagen type-1 cross-linked N-telopeptide (NTX);
• Urine or serum collagen type-1 cross-linked C-telopeptide (CTX);
• Bone sialoprotein (BSP);
• Tartrate-resistant acid phosphatase 5b.

bone marker

Lab medicine Any protein degradation product that indicates bone breakdown. See N-telopeptides.
Mentioned in ?
References in periodicals archive ?
A good biochemical bone marker should have minimal non-modifiable bio variability.
This dose-ranging study will commence in the first half of this year and will include bone marker, bone mineral density and safety endpoints.
The clinical utility of bone marker measurements in osteoporosis.
They also suggested that the term 'osteopenia' or 'low bone mass' be applied when T scores are from -1.0 to -2.5.12 As a result of the increased bone turnover, as seen in postmenopausal women, the biochemical bone marker concentration is also altered in blood and urine.13
No significant difference was found between subjects with and without depression in terms of 24-hour urinary cortisol levels, bone marker levels, and BMDs.
For each bone marker, the variation index recorded during the follow-up has been considered according to the final outcome.
We then imported and transformed the RSA bone marker dataset into a set of "RSA-based bone landmarks" in the CT coordinate system.
The serum was aliquoted into microtubes, and frozen at -84[degrees]C until the bone marker assays were performed.
It increases the growth of cells called osteoblasts, which help build your bones, and increases expression of collagen and bone marker proteins.
We show that this prevention in areal bone mineral density and micro-CT parameters results from the stimulation of bone formation, demonstrable in vivo by histomorphometry, bone marker measurements, and quantitative PCR.
On Tuesday, Algeta announced positive preliminary bone marker results in a phase IIa study evaluating the drug in breast cancer patients with bone metastases.